Prolymphocytic leukemia (PLL) is a rare, fast-moving blood cancer in which large, immature-looking lymphocytes called prolymphocytes flood the blood, bone marrow and spleen. Diagnosing and treating prolymphocytic leukemia depends first on which cell type is involved: the T-cell form is treated with the antibody alemtuzumab followed, when possible, by a stem cell transplant, while B-cell cases are now usually managed like other B-cell cancers with targeted drugs. Below I walk through how the disease behaves, how it is confirmed, and what treatment looks like in practice.
What Is Prolymphocytic Leukemia?
Prolymphocytic leukemia is a mature lymphoid leukemia, meaning the cancerous cells come from lymphocytes that have already passed the earliest stages of development. Under the microscope, a prolymphocyte is larger than a normal lymphocyte, with a single prominent nucleolus in the middle of its nucleus.
It is one of the less common hematologic disorders, and it mostly affects older adults, typically over 60. Unlike chronic lymphocytic leukemia (CLL), which can sit quietly for years, PLL usually progresses over weeks to months, which is why prompt diagnosis matters.
The disease starts in the bone marrow and spills into the blood. As prolymphocytes crowd the marrow, production of normal red cells and platelets falls, which explains much of the anemia and bruising patients experience.
The Two Subtypes
PLL is split according to the lymphocyte it comes from. T-cell prolymphocytic leukemia (T-PLL) is the more common of the two and is a distinct disease with its own genetic signature. B-cell prolymphocytic leukemia (B-PLL) is rarer still.
In the most recent World Health Organization classification, B-PLL is no longer listed as a separate disease. Most cases once labeled B-PLL are now recognized as mantle cell lymphoma, CLL that has transformed toward prolymphocytes, or a splenic B-cell lymphoma. This matters because the correct label points to the correct treatment.
| Feature | T-PLL | B-PLL |
|---|---|---|
| Cell of origin | Mature T lymphocyte | Mature B lymphocyte |
| Typical white cell count | Very high, often above 100,000 per microliter | Very high |
| Spleen | Enlarged | Often massively enlarged |
| Lymph nodes | Commonly enlarged | Usually little enlargement |
| Other features | Skin rash, swelling around the eyes, fluid around lungs | Few features outside blood and spleen |
| Key genetic change | TCL1 rearrangement on chromosome 14 | Variable; TP53 changes common |
| Usual first treatment | Alemtuzumab, then transplant if fit | CLL-style targeted therapy |
Causes and Risk Factors
No lifestyle or environmental cause for PLL has been established. The disease arises from acquired genetic damage inside a single lymphocyte, not from anything a person inherited or did.
In T-PLL, the hallmark change is a rearrangement of chromosome 14, either an inversion of chromosome 14 or a translocation between the two copies of chromosome 14. This switches on a gene called TCL1, which drives cell survival. Extra copies of part of chromosome 8 and loss of the ATM gene are also frequent.
The main risk factor is age. People with ataxia-telangiectasia, an inherited condition caused by ATM mutations, have a higher risk of T-cell leukemias, but this accounts for very few cases.
Symptoms of Prolymphocytic Leukemia
Symptoms tend to build quickly. The most common are:
- Fatigue and breathlessness from anemia
- Splenomegaly, an enlarged spleen causing fullness or pain under the left ribs and early satiety
- Night sweats, fevers and unintended weight loss
- Easy bruising or bleeding from a low platelet count
- Swollen lymph nodes, more typical of T-PLL
- In T-PLL, a skin rash, puffiness around the eyes, or fluid collecting around the lungs
Many patients are first flagged because a routine blood count shows a very high lymphocyte count. In my practice, that single result, combined with a big spleen, is often the first clue.
How PLL Is Diagnosed
Confirming PLL uses several hematological tests together, because no single test is enough.
- Complete blood count: shows a markedly raised lymphocyte count, often with anemia and low platelets.
- Blood smear: a hematologist looks for prolymphocytes. Traditionally, PLL is diagnosed when prolymphocytes make up more than 55% of the lymphoid cells in the blood.
- Flow cytometry: this test reads the protein markers on the cell surface. T-PLL cells carry T-cell markers such as CD2, CD3, CD5 and CD7, and most are CD4-positive. It separates T-PLL from B-cell diseases and from CLL.
- Cytogenetics and molecular tests: look for the chromosome 14 rearrangement, TP53 changes and other markers that guide treatment and prognosis.
- Imaging: ultrasound or CT measures the spleen and lymph nodes.
- Bone marrow biopsy: not always required when the blood findings are clear, but it helps show how much the marrow is involved.
Treating Prolymphocytic Leukemia
Treatment starts soon after diagnosis in most patients, because the disease rarely stays stable. A small group with no symptoms and slowly rising counts may be watched closely for a short period, but this is the exception.
T-PLL Treatment
The standard first treatment is alemtuzumab, an antibody that targets the CD52 protein found in large amounts on T-PLL cells. It is given intravenously and achieves remission in most patients. Because it suppresses the immune system strongly, patients receive preventive antibiotics and antivirals, and they are monitored for reactivation of cytomegalovirus.
Remissions with alemtuzumab alone tend not to last. For fit patients, the plan is to move on to an allogeneic stem cell transplant, using cells from a donor, while in first remission. This is currently the only approach with a realistic chance of long-term control.
B-PLL Treatment
Because B-cell cases are now usually reclassified, treatment follows the underlying diagnosis. Older approaches used fludarabine-based chemotherapy with rituximab. Today, many patients receive targeted drugs used in CLL, such as BTK inhibitors like ibrutinib or the BCL-2 inhibitor venetoclax, which work even when TP53 is damaged. Removing or irradiating a very large spleen can ease symptoms in selected cases.
Supportive Care
Alongside cancer treatment, patients may need red cell or platelet transfusions, infection prevention and vaccinations (avoiding live vaccines). Clinical trials of newer targeted drugs are worth asking about, as the rarity of the disease makes trial access especially valuable.
Outlook and Recent Research
PLL has historically carried a guarded prognosis, especially T-PLL. Outcomes are best in patients who respond well to first treatment and go on to transplant. Age, overall fitness and genetic findings all shape the individual outlook, so it is best discussed with the treating team.
Research into the biology of PLL has identified pathways, such as JAK-STAT signaling in T-PLL, that are being tested as drug targets. Combinations of existing targeted agents are also under study. These remain investigational, but they reflect how hematology is moving toward treatment matched to the genetics of each leukemia. For a broader overview of related conditions, see our leukemia guide.
Key Takeaways
- PLL is a rare, aggressive leukemia of large, immature-looking lymphocytes, seen mainly in older adults.
- T-PLL is the more common subtype; B-PLL is now usually reclassified as another B-cell disease.
- Diagnosis combines a blood count, smear review, flow cytometry and genetic testing.
- T-PLL is treated with alemtuzumab, followed by donor stem cell transplant in fit patients.
- See a doctor promptly for a rapidly enlarging spleen, drenching night sweats, weight loss or unexplained bruising.
Frequently Asked Questions
Is prolymphocytic leukemia the same as CLL?
No. Both involve mature lymphocytes, but PLL cells look different under the microscope and the disease moves much faster. CLL can occasionally transform so that prolymphocytes increase, and this is now treated as a progression of CLL rather than true PLL.
Can prolymphocytic leukemia be cured?
For T-PLL, a donor stem cell transplant performed in first remission offers the best chance of long-term disease control. Without transplant, remissions usually do not last. Whether transplant is possible depends on age, fitness and donor availability.
How is alemtuzumab given?
Alemtuzumab is given as an intravenous infusion, usually several times a week over a number of weeks. Early doses can cause fever and chills, so they are started at low dose and increased. Infection prevention medicines are taken throughout.
Is PLL inherited?
Almost never. The genetic changes develop in a single cell during life and are not passed on to children. The rare exception is the higher risk seen in people with inherited ataxia-telangiectasia.
